Categories Earnings, Health Care

Medtronic to announce Q4 results amidst pacemaker crisis

Medtronic (NYSE: MDT) is scheduled to report fourth-quarter 2019 financial results on Thursday, May 23, before the regular trading hours. The Dublin-based firm is expected to report earnings of $1.46 per share on revenues of $8.12 billion.

The compares with the earnings of $1.42 per share and revenues of $8.1 billon it reported in the same period last year.

MDT shares have been almost flat so far this year, fluctuating between $82 and $93. In the trailing 52 weeks, the stock has returned a lackluster 2.3% growth.

The fourth quarter results come at a time when the medical device maker is embroiled in allegations that some of its pacemakers run out of charge without giving a warning to the patients, causing medical emergencies.

Earlier this month, the US Food and Drug Administration raised an alarm on pacemaker models Azure, Astra, Percepta, Serena and Solara for pre-mature battery depletion, though a recall wasn’t ordered. Two weeks later, a similar panel in India echoed the same concerns over Medtronic devices.

The management is likely to speak in detail about the issue as they go live during the earnings conference call.  

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

In Q4, investors will be looking at the growth of its cardiac and vascular group, as well as the diabetes unit, both of which are projected to drive long-term traffic for the company.

Of late, Medtronic has been trying to diversify its portfolio to offset weakness in certain areas of medical devices. The most recent move in this regard was the acquisition of Titan Spine, a company that makes titanium spine interbody implant.

This deal was announced last week.

In the last reported quarter, Medtronic topped consensus estimates on revenue and earnings for the and raised its earnings guidance for the fiscal year 2019. Shares were up 0.79% in premarket hours on Tuesday.

Worldwide revenues totaled $7.5 billion, up 2.4% from the same period last year. On an organic basis, revenues grew 4.4%. Adjusted net income rose 10% to $1.75 billion, or $1.29 per share.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top